Abstract:Adoptive T-cell transfer (ACT) therapies, including of tumor infiltrating lymphocytes (TILs) and T cells gene-modified to express either a T cell receptor (TCR) or a chimeric antigen receptor (CAR), have demonstrated clinical efficacy for a proportion of patients and cancer-types. The field of ACT has been driven forward by the clinical success of CD19-CAR therapy against various advanced B-cell malignancies, including curative responses for some leukemia patients. However, relapse remains problematic, in particular for lymphoma. Moreover, for a variety of reasons, relative limited efficacy has been demonstrated for ACT of non-hematological solid tumors. Indeed, in addition to pre-infusion challenges including lymphocyte collection and manufacturing, ACT failure can be attributed to several biological processes post-transfer including, (i) inefficient tumor trafficking, infiltration, expansion and retention, (ii) chronic antigen exposure coupled with insufficient costimulation resulting in T-cell exhaustion, (iii) a range of barriers in the tumor microenvironment (TME) mediated by both tumor cells and suppressive immune infiltrate, (iv) tumor antigen heterogeneity and loss, or down-regulation of antigen presentation machinery, (v) gain of tumor intrinsic mechanisms of resistance such as to apoptosis, and (vi) various forms of toxicity and other adverse events in patients. Affinity-optimized TCRs can improve T-cell function and innovative CAR designs as well as gene-modification strategies can be used to coengineer specificity, safety, and function into T cells. Coengineering strategies can be designed not only to directly support the transferred T cells, but also to block suppressive barriers in the TME and harness endogenous innate and adaptive immunity. Here, we review a selection of the remarkable T-cell coengineering strategies, including of tools, receptors, and gene-cargo, that have been developed in recent years to augment tumor control by ACT, more and more of which are advancing to the clinic.

Adoptive Immunotherapy beyond CAR T-Cells

Chimeric Antigen Receptor Natural Killer Cells: a Promising Antitumor Immunotherapy

Application of CAR-T Cell Therapy beyond Oncology: Autoimmune Diseases and Viral Infections

Adoptive Cell Therapy—Harnessing Antigen-Specific T Cells to Target Solid Tumours

Adoptive CD8+ T cell therapy against cancer:Challenges and opportunities

Adoptive T cell therapy for solid tumors: current landscape and future challenges

Safety and Tolerability of Adoptive Cell Therapy in Cancer

Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T

Challenges and new technologies in adoptive cell therapy

Adoptive T-cell Therapy of B-cell Malignancies: Conventional and Physiological Chimeric Antigen Receptors.

Coengineering specificity, safety, and function into T cells for cancer immunotherapy

Adoptive cell therapy for solid tumors beyond CAR-T: Current challenges and emerging therapeutic advances

Current and future concepts for the generation and application of genetically engineered CAR-T and TCR-T cells

Harnessing the tumor microenvironment to boost adoptive T cell therapy with engineered lymphocytes for solid tumors

Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer

T cell receptor‐based cancer immunotherapy: Emerging efficacy and pathways of resistance

CAR T cell immunotherapy for human cancer

TCR Redirected T Cells for Cancer Treatment: Achievements, Hurdles, and Goals

Advancements in adoptive CAR immune cell immunotherapy synergistically combined with multimodal approaches for tumor treatment

Recent advances and clinical pharmacology aspects of Chimeric Antigen Receptor (CAR) T-cellular therapy development

Optimising CAR T therapy for the treatment of solid tumors